Management of Debris-Laden Histiocytes on Bone Marrow
Diagnostic Approach
- The American Society of Hematology recommends performing a complete patient history to exclude reactive causes of histiocytic infiltration, particularly infectious diseases and solid tumors 1, 2
- A thorough physical examination should be conducted with special attention to spleen size, presence of cutaneous lesions, and lymphadenopathy 1, 3, 4
- Complete blood count with peripheral blood smear examination and differential leukocyte count is necessary 1
- Evaluate for persistent monocytosis, which may indicate chronic myelomonocytic leukemia (CMML) 5
Bone Marrow Evaluation
- Bone marrow aspiration and biopsy should be performed with staining, including hematoxylin-eosin, immunostaining for CD34+ and monocytic cells, and Gomori's silver impregnation for fibrosis 1, 6, 7
- Assess for marrow cellularity, presence of dysplasia, blast percentage, megakaryocyte morphology, and bone marrow fibrosis 1, 5, 7, 8
Laboratory and Molecular Testing
- Conventional cytogenetic analysis should be conducted to detect clonal chromosomal abnormalities 1
- Molecular assays should be performed to exclude BCR/ABL fusion gene and rearrangements of PDGFRA and PDGFRB 1, 3
- Consider testing for mutations commonly associated with CMML, including NRAS, KRAS, TET2, CBL, SRSF2 genes, and JAK2 V617F mutations 3, 7
Differential Diagnosis
- Chronic Myelomonocytic Leukemia (CMML) is characterized by persistent peripheral blood monocytosis and dysplasia in one or more myeloid lineages 3, 5, 7
- Histiocytic Neoplasms, such as Erdheim-Chester Disease (ECD), may present with foamy histiocytes and BRAF V600E mutation 1, 4
Management Strategy
- For CMML, risk stratification using CPSS-Mol and consideration of allogeneic hematopoietic stem cell transplantation for high-risk disease 8
- For Histiocytic Neoplasms, management depends on the specific disorder, and BRAF inhibitors may be considered for ECD and LCH with BRAF V600E mutation 1, 4